Bavachin is a component purified from ethanolic extract of Psoralea corylifolia. It activates estrogen receptors ERα and ERβ in Cv-1 cells with EC50 values of 320 nM and 680 nM, respectively. Bavachin displaced the [3H] E2 with IC50 values of 6.57×10-5M and 3.8×10-5M for hERα and hERβ, respectively. The treatment with breast cancer cell line MCF-7 with 10 μM bavachin for 12 h downregulated the protein level of ERα compared to the vehicle control. In MCF-7 BOS cells, treatment with bavachin (0.01 - 1 μM) for 6 days significantly induced cellular proliferation in a dose-dependent manner[3]. In ovariectomized (OVX) rats, treatment with Bavachin (8 mg/kg/day) for 12 weeks significantly reduced the serum level of alkaline phosphatase and increased the level of N-terminal propeptide of procollagen type I compared to the vehicle control group. The administration of bavachin also increased the thickness and integrality of cortical bone in OVX rats[4].
Bavachin/补骨脂二氢黄酮 细胞实验
Cell Line
Concentration
Treated Time
Description
References
Huh7 cells
20 μM
24 h
Significantly suppressed PA/OA or high glucose/high insulin-induced increases in the expression of fatty acid synthesis-related genes and the number and size of lipid droplets. Furthermore, bavachin treatment markedly elevated the phosphorylation levels of AKT and GSK-3β, improving the insulin signaling activity in the cells.
Acta Pharmacol Sin. 2023 Jul;44(7):1416-1428
human renal tubular epithelial HK-2 cells
0.1 μg/mL
1 h
To investigate the effect of Bavachin on LPS-induced expression of kidney injury markers NGAL and KIM-1. Results showed that Bavachin pretreatment significantly inhibited the LPS-induced increase in NGAL and KIM-1 expression.
Antioxidants (Basel). 2022 Oct 24;11(11):2096
Bavachin/补骨脂二氢黄酮 动物实验
Species
Animal Model
Administration
Dosage
Frequency
Description
References
C57BL/6J mice
HFD-induced obese mice model
Intraperitoneal injection
30 mg/kg
Every other day for 8 weeks
Efficiently attenuated the increases in body weight, liver weight, blood glucose, and liver and serum triglyceride contents. Moreover, bavachin administration significantly alleviated hepatic inflammation and ameliorated HFD-induced glucose intolerance and insulin resistance. We demonstrated that bavachin protected against HFD-induced obesity by inducing fat thermogenesis and browning subcutaneous white adipose tissue (subWAT).
Acta Pharmacol Sin. 2023 Jul;44(7):1416-1428
Mice
DEX-induced muscle atrophy model and db/db diabetic mice model
Oral
10 mg/kg
Once daily for 12 days (DEX model) or 40 days (db/db model)
Bavachin enhanced muscle strength and muscle mass, suppressed inflammatory cytokine expression, and improved mitochondrial quality control
Antioxidants (Basel). 2023 Jan 6;12(1):137
C57BL/6 mice
LPS-induced acute kidney injury (AKI) model
Oral
10 and 20 mg/kg
Once daily for seven days
To evaluate the protective effect of Bavachin on LPS-induced acute kidney injury. Results showed that Bavachin pretreatment significantly inhibited the increase in serum creatinine and blood urea nitrogen levels, improved kidney injury scores, and reduced the expression of tubular injury markers NGAL and KIM-1.
搜索
